中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
17期
57-60
,共4页
卢衡凭%邓治洲%龙孝斌%郭仪
盧衡憑%鄧治洲%龍孝斌%郭儀
로형빙%산치주%룡효빈%곽의
重组人血管内皮抑素%薄芝糖肽%奥沙利铂%培美曲塞%非小细胞肺癌%临床疗效%免疫功能
重組人血管內皮抑素%薄芝糖肽%奧沙利鉑%培美麯塞%非小細胞肺癌%臨床療效%免疫功能
중조인혈관내피억소%박지당태%오사리박%배미곡새%비소세포폐암%림상료효%면역공능
Recombinant human endostatin%Bozhi glycopeptide%Oxaliplatin%Pemetrexed%Non-small cell lung cancer%Clinical curative effect%Immune function
目的：探讨重组人血管内皮抑素与薄芝糖肽联合化疗治疗晚期非小细胞肺癌的近期临床效果和安全性。方法选取2012年1月~2014年4月来本院就诊的102例经病理证实的晚期非小细胞肺癌患者，根据治疗方法，将患者分为两组。对照组48例单纯给予奥沙利铂(L-OHP)+培美曲塞(PEM)化疗方案；实验组54例在对照组基础上给予重组人血管内皮抑素和薄芝糖肽治疗。比较两组患者的临床疗效、生活质量KPS评分、药物毒性反应发生率以及外周血免疫功能变化情况。结果治疗后，实验组患者的近期临床疗效、生活质量KPS评分优于对照组(P<0.05)。两组患者治疗后的CD4+、CD8+均较治疗前降低，对照组降低更明显，两组治疗后的CD4+、CD8+差异有统计学意义(P<0.05)。结论重组人血管内皮抑素与薄芝糖肽联合化疗治疗晚期非小细胞肺癌具有较好的近期效果，能提高患者在化疗过程中的生活质量，改善其免疫功能。
目的：探討重組人血管內皮抑素與薄芝糖肽聯閤化療治療晚期非小細胞肺癌的近期臨床效果和安全性。方法選取2012年1月~2014年4月來本院就診的102例經病理證實的晚期非小細胞肺癌患者，根據治療方法，將患者分為兩組。對照組48例單純給予奧沙利鉑(L-OHP)+培美麯塞(PEM)化療方案；實驗組54例在對照組基礎上給予重組人血管內皮抑素和薄芝糖肽治療。比較兩組患者的臨床療效、生活質量KPS評分、藥物毒性反應髮生率以及外週血免疫功能變化情況。結果治療後，實驗組患者的近期臨床療效、生活質量KPS評分優于對照組(P<0.05)。兩組患者治療後的CD4+、CD8+均較治療前降低，對照組降低更明顯，兩組治療後的CD4+、CD8+差異有統計學意義(P<0.05)。結論重組人血管內皮抑素與薄芝糖肽聯閤化療治療晚期非小細胞肺癌具有較好的近期效果，能提高患者在化療過程中的生活質量，改善其免疫功能。
목적：탐토중조인혈관내피억소여박지당태연합화료치료만기비소세포폐암적근기림상효과화안전성。방법선취2012년1월~2014년4월래본원취진적102례경병리증실적만기비소세포폐암환자，근거치료방법，장환자분위량조。대조조48례단순급여오사리박(L-OHP)+배미곡새(PEM)화료방안；실험조54례재대조조기출상급여중조인혈관내피억소화박지당태치료。비교량조환자적림상료효、생활질량KPS평분、약물독성반응발생솔이급외주혈면역공능변화정황。결과치료후，실험조환자적근기림상료효、생활질량KPS평분우우대조조(P<0.05)。량조환자치료후적CD4+、CD8+균교치료전강저，대조조강저경명현，량조치료후적CD4+、CD8+차이유통계학의의(P<0.05)。결론중조인혈관내피억소여박지당태연합화료치료만기비소세포폐암구유교호적근기효과，능제고환자재화료과정중적생활질량，개선기면역공능。
Objective To explore short-term clinical efficacy and safety of recombinant human endostatin and bozhi glycopeptide combined with chemotherapy scheme in the treatment of advanced non-small cell lung cancer. Methods From January 2012 to April 2014,102 patients admitted into our hospital and confirmed as advanced non-small cell lung cancer by pathological diagnosis were divided into two groups.The control group (48 patients) was given chemotherapy scheme of oxaliplatin (L-OHP)+pemetrexed (PEM).The experiment group (54 patients) were given recom-binant human endostatin and bozhi glycopeptide on the basis of control group.Then the clinical effect,KPS score of life quality,the incidence rate of drug toxicity reaction and the change of immune function of peripheral blood between two groups was compared respectively. Results After treatment,short-term clinical effect and KPS score of life quality of the experiment group was better than that of control group respectively (P<0.05).CD4+,CD8+after treatment in patients of two groups was decreased respectively compared with before treatment,and control group was more obvious,and there was a statistical difference of CD4+,CD8+after treatment between two groups (P<0.05). Conclusion Recombinant human endostatin combined with bozhi glycopeptide has a better short-term effect in the treatment of advanced non-small cell lung cancer and can enhance patients’life quality in the process of chemical therapy and improve the immune function of patients.
